These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 26808478)
1. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. Zhao XZ; Smith SJ; Maskell DP; Metifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR ACS Chem Biol; 2016 Apr; 11(4):1074-81. PubMed ID: 26808478 [TBL] [Abstract][Full Text] [Related]
2. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381 [TBL] [Abstract][Full Text] [Related]
3. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms. Engelman AN; Cherepanov P FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843 [TBL] [Abstract][Full Text] [Related]
4. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors. Zhao XZ; Smith SJ; Maskell DP; Métifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR J Med Chem; 2017 Sep; 60(17):7315-7332. PubMed ID: 28737946 [TBL] [Abstract][Full Text] [Related]
5. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464 [TBL] [Abstract][Full Text] [Related]
6. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH Viruses; 2021 Jan; 13(2):. PubMed ID: 33572956 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Hare S; Vos AM; Clayton RF; Thuring JW; Cummings MD; Cherepanov P Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20057-62. PubMed ID: 21030679 [TBL] [Abstract][Full Text] [Related]
8. HIV drug resistance against strand transfer integrase inhibitors. Anstett K; Brenner B; Mesplede T; Wainberg MA Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191 [TBL] [Abstract][Full Text] [Related]
9. 2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance. Desimmie BA; Demeulemeester J; Suchaud V; Taltynov O; Billamboz M; Lion C; Bailly F; Strelkov SV; Debyser Z; Cotelle P; Christ F ACS Chem Biol; 2013; 8(6):1187-94. PubMed ID: 23517458 [TBL] [Abstract][Full Text] [Related]
10. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. Xue W; Jin X; Ning L; Wang M; Liu H; Yao X J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029 [TBL] [Abstract][Full Text] [Related]
11. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition. Engelman AN J Biol Chem; 2019 Oct; 294(41):15137-15157. PubMed ID: 31467082 [TBL] [Abstract][Full Text] [Related]
12. The development of novel HIV integrase inhibitors and the problem of drug resistance. Wainberg MA; Mesplède T; Quashie PK Curr Opin Virol; 2012 Oct; 2(5):656-62. PubMed ID: 22989757 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants. Smith SJ; Zhao XZ; Passos DO; Pye VE; Cherepanov P; Lyumkis D; Burke TR; Hughes SH ACS Infect Dis; 2021 Jun; 7(6):1469-1482. PubMed ID: 33686850 [TBL] [Abstract][Full Text] [Related]
14. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Cutillas V; Mesplede T; Anstett K; Hassounah S; Wainberg MA Antimicrob Agents Chemother; 2015 Jan; 59(1):310-6. PubMed ID: 25348535 [TBL] [Abstract][Full Text] [Related]
15. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses. Witmer M; Danovich R Methods; 2009 Apr; 47(4):277-82. PubMed ID: 19286458 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants. Li M; Oliveira Passos D; Shan Z; Smith SJ; Sun Q; Biswas A; Choudhuri I; Strutzenberg TS; Haldane A; Deng N; Li Z; Zhao XZ; Briganti L; Kvaratskhelia M; Burke TR; Levy RM; Hughes SH; Craigie R; Lyumkis D Sci Adv; 2023 Jul; 9(29):eadg5953. PubMed ID: 37478179 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation. De Luca L; De Grazia S; Ferro S; Gitto R; Christ F; Debyser Z; Chimirri A Eur J Med Chem; 2011 Feb; 46(2):756-64. PubMed ID: 21227550 [TBL] [Abstract][Full Text] [Related]
18. MK-0536 inhibits HIV-1 integrases resistant to raltegravir. Métifiot M; Johnson B; Smith S; Zhao XZ; Marchand C; Burke T; Hughes S; Pommier Y Antimicrob Agents Chemother; 2011 Nov; 55(11):5127-33. PubMed ID: 21876054 [TBL] [Abstract][Full Text] [Related]
19. HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors. Koneru PC; Francis AC; Deng N; Rebensburg SV; Hoyte AC; Lindenberger J; Adu-Ampratwum D; Larue RC; Wempe MF; Engelman AN; Lyumkis D; Fuchs JR; Levy RM; Melikyan GB; Kvaratskhelia M Elife; 2019 May; 8():. PubMed ID: 31120420 [TBL] [Abstract][Full Text] [Related]